RxDoctor Payments Data

Michael de Vita, DO

Cardiovascular Disease · Brick, NJNPI 1790766277

Payments from drug & device makers

$17,556in general payments, 2019–2025

Across 329 payments — averaging $53.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GE HealthCare$12K
  • Abbott$1K
  • Johnson & Johnson$477
  • Amgen$476
  • Novo Nordisk$357
  • Boston Scientific$322
  • plus $3K from 34 others

What the payments were for

  • Consulting fees$8,55149%
  • Speaking & faculty fees$3,43220%
  • Food & beverage$5,57332%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,556 in reported general payments places this provider in the 80th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$786,801
Medicare patients
2,673
Services billed
8,562

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban457$571,974
XareltoRivaroxaban93$129,756
Repatha SureclickEvolocumab53$75,394
EntrestoSacubitril/Valsartan27$37,949
JardianceEmpagliflozin24$33,170
OzempicSemaglutide19$25,210
Ezetimibe768$21,472
BrilintaTicagrelor29$21,405
MultaqDronedarone Hcl17$21,131
FarxigaDapagliflozin Propanediol11$12,179
Icosapent Ethyl16$11,694
Metoprolol Succinate587$8,230
Rosuvastatin Calcium545$7,653
Valsartan160$5,626
Atorvastatin Calcium506$5,403

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$143$571,974457 claims
Johnson & JohnsonXarelto$477$129,75693 claims
NovartisEntresto$251$37,94927 claims
AstraZenecaBrilinta, Farxiga$193$33,58440 claims
Boehringer IngelheimJardiance$290$33,17024 claims
Novo NordiskOzempic$357$25,21019 claims
Sanofi-aventis U.S. LLCMultaq$101$21,13117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Brick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →